北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel） 010-88004488/66090088 传真（Fax): 010-66090016 北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划首次授予部分 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划首次授予部分 第二个解除限售期、预留授予部分第一个解除限售期 解除限售条件成就及回购注销事项的 法律意见书 国枫律证字[2023]AN138-7 号 GRANDWAY 北京国枫律师事务所 第二个解除限售期、预留授予部分第一个解除限售期 解除限售条件成就及回购注销事项的 法律意见书 国枫律证字[2023] AN138-7号 致:北京康辰药业股份有限公司 根据本所与康辰药业签署的《律师服务协议书》,本所接受康辰药业的委托,担 任康辰药业本次股权激励计划的特聘专项法律顾问,并已出具了《北京国枫律师事 务所关于北京康辰药业股份有限公司 2023 年限制性股票激励计划(草案)的法律意 见书》《北京国枫律师事务所关于北京康辰药 ...

Core Insights - Kangchen Pharmaceutical's stock price increased by 2.02% on September 12, reaching 54.15 CNY per share, with a total market capitalization of 8.629 billion CNY [1] - The company has seen a year-to-date stock price increase of 136.25%, but has experienced a decline of 4.88% over the last five trading days [1] Financial Performance - For the first half of 2025, Kangchen Pharmaceutical reported a revenue of 461 million CNY, representing a year-on-year growth of 13.79% [2] - The net profit attributable to shareholders for the same period was 91.046 million CNY, reflecting a year-on-year increase of 14.95% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 10.82% to 9,970, while the average number of circulating shares per person increased by 12.14% to 15,771 shares [2] - The company has distributed a total of 437 million CNY in dividends since its A-share listing, with 175 million CNY distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Penghua Medical Technology Stock A, which increased its holdings by 354,600 shares, and new entrants such as E Fund Healthcare Industry Mixed A and CITIC Jiantou Medical Reform A [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.7% on September 10, with Kangchen Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Baipusais (301080) with a closing price of 60.80, up 7.04% [1] - Aopumai (688293) with a closing price of 52.54, up 3.02% [1] - ST Weiming (002581) with a closing price of 7.83, up 1.56% [1] - Significant decliners included: - Kangchen Pharmaceutical (603590) with a closing price of 52.17, down 5.06% [2] - Wo Wu Biological (300357) with a closing price of 31.59, down 4.45% [2] - Aidi Pharmaceutical (688488) with a closing price of 15.68, down 3.80% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 444 million yuan from institutional investors, while retail investors contributed a net inflow of 269 million yuan [2] - The capital flow for individual stocks showed: - Kangtai Biological (300601) had a net inflow of 31.13 million yuan from institutional investors [3] - Junshi Biological (688180) experienced a net outflow of 12.11 million yuan from retail investors [3] - Wanzhe Co. (000534) had a net inflow of 14.46 million yuan from institutional investors [3]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) announced a share reduction plan by its controlling shareholder Liu Jianhua due to personal funding needs, intending to reduce up to 4,780,693 shares, which is no more than 3% of the total shares [1][2]. Summary by Relevant Sections Share Reduction Plan - Liu Jianhua plans to reduce his holdings through centralized bidding and block trading methods, with a total reduction not exceeding 4,780,693 shares [1][2]. - The reduction will occur within three months after a 15 trading day period following the announcement, excluding any legally prohibited reduction periods [1]. - The maximum number of shares that can be reduced via centralized bidding is 1% of the total shares within any consecutive 90-day period, while block trading can account for up to 2% [1][2]. Financial Implications - Based on the closing price of 56.93 yuan on September 5, the total amount from the planned reduction is approximately 272 million yuan [2]. Company Background - Kangchen Pharmaceutical was listed on the Shanghai Stock Exchange on August 27, 2018, with an initial issuance of 40 million shares, representing 25% of the total shares post-IPO [3]. - The company raised a total of 973.6 million yuan, with a net amount of 891.43 million yuan intended for various projects, including innovative drug research and production capacity expansion [3].

Summary of Key Points Core Viewpoint - On September 5, Guizhou Moutai disclosed its shareholding increase, while 24 listed companies announced shareholding reductions, indicating a mixed sentiment in the market regarding stock performance and investor confidence [1][2]. Group 1: Shareholding Increases - Guizhou Moutai's controlling shareholder, Moutai Group, received a commitment letter for a loan of up to 2.7 billion yuan from Agricultural Bank [2]. Group 2: Shareholding Reductions - A total of 24 companies reported shareholding reductions, including: - Aohai Technology: Shareholder plans to reduce holdings by up to 7 million shares [2]. - Ruihu Mould: Shareholder plans to reduce up to 3% of company shares [2]. - Guanghua Technology: Some executives plan to reduce a total of up to 477.81 thousand shares [2]. - Kaipu Detection: Vice President plans to reduce company shares [2]. - Liren Technology: Controlling shareholder plans to reduce up to 3% of shares [2]. - Tonghuashun: Controlling shareholder plans to reduce a total of up to 0.26% of shares [2]. - Kexin Innovation Source: One of the actual controllers plans to reduce up to 141.5 thousand shares [2]. - Other companies such as Feima International, Changjiang Materials, and others also reported various plans for share reductions [2].

Key Points - China Petroleum & Chemical Corporation (Sinopec) announced a cash dividend of RMB 0.088 per share, totaling RMB 10.662 billion [4] - Guokai Microelectronics is progressing with a share issuance and cash payment to acquire 94.366% of the equity in Zhongxin Integrated Circuit (Ningbo) Co., Ltd. [5][6] - Phoenix Shipping's Vice General Manager Zhao Qiuling resigned due to work adjustments, while Wang Guozheng was appointed as the new financial director [7] - Guokai Co., Ltd. changed its stock abbreviation to Guokai Electronics, effective September 11, 2025 [8] - Xinhua Pharmaceutical's Vice General Manager Zheng Zhonghui resigned for personal reasons, holding 397,600 shares [9] - Uni-President's controlling shareholder's equity structure change was completed, transferring shares from the Ministry of Finance to Central Huijin Investment [10] - ST New Power may face delisting risk due to a negative audit opinion on its internal controls [11] - Huachuang Yuxin announced that 1.87% of its shares held by Shanghai Shiran Industrial Co., Ltd. will be auctioned [12][13] - Zhengbang Technology's subsidiary was accepted for reorganization by the court due to financial difficulties [14] - China Shipbuilding Defense's General Manager Chen Liping resigned due to work changes [15] - ST Lingnan and its former controlling shareholder are under investigation for information disclosure violations [16] - Hikvision's chairman proposed a mid-term dividend of RMB 4 per 10 shares, amounting to RMB 3.666 billion [17] - Huada Jiutian's shareholder plans to transfer 2.64% of the company's shares [18] - Poly Developments reported a signing amount of RMB 18.015 billion in August, a year-on-year decrease of 18.54% [19] - Muyuan Foods reported a revenue of RMB 11.85 billion from selling 7.001 million pigs in August, a year-on-year decrease of 12.30% [20] - Dongrui Co., Ltd. reported a revenue of RMB 160 million from selling 94,800 pigs in August, a month-on-month decrease of 5.48% [21] - Ankai Bus reported a cumulative production increase of 68.06% year-on-year [22] - Kweichow Moutai's controlling shareholder received a loan commitment of up to RMB 2.7 billion for stock repurchase [23] - Chengda Pharmaceutical's major shareholder plans to reduce its stake by 7.27% [24][25] - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 3% [26] - Koweil plans to reduce its stake by up to 2.34% [27] - Funeng Technology's shareholders plan to reduce their stake by up to 2% [28] - United Water's shareholder plans to reduce its stake by 3% [29] - Huayin Power's shareholder plans to reduce its stake by 1% [30] - Tianji Co., Ltd. reported a reduction of 0.61% in its controlling shareholder's stake [31] - Tonghuashun's controlling shareholder plans to reduce its stake by up to 138,310 shares [32] - JA Solar has not yet started its share repurchase plan [33] - Beite Technology plans to raise no more than RMB 300 million through a private placement [34] - Aerospace Hongtu signed a strategic cooperation agreement with Pakistan worth RMB 2.9 billion, which is still in preliminary stages [35][36] - Guangqi Technology signed contracts for mass production of metamaterials worth RMB 1.278 billion [37]

Core Viewpoint - Kangchen Pharmaceutical (603590) announced that its controlling shareholder, Liu Jianhua, plans to reduce his stake in the company due to personal funding needs, with a total reduction not exceeding 4.78 million shares, which is 3% of the company's total shares [1] Group 1 - The announcement was made on the evening of September 5 [1] - The reduction will occur through centralized bidding and block trading methods [1] - The total number of shares Liu Jianhua intends to sell is capped at 4.78 million [1]

分组1 - Sinopec announced a cash dividend of RMB 0.088 per share (tax included) for the first half of 2025, with a total cash dividend distribution of RMB 10.662 billion [3] - Guokai Microelectronics is progressing with the acquisition of a 94.366% stake in Zhongxin Integrated Circuit (Ningbo) Co., Ltd. through a combination of share issuance and cash payment [4] - Phoenix Shipping's Vice President Zhao Qiuling resigned due to work adjustments, while Wang Guozheng was appointed as the new CFO [5] 分组2 - Guokai Microelectronics is actively advancing its major asset restructuring, with due diligence and evaluation processes underway [4] - The stock name of Guokai Co., Ltd. will change to Guokai Electronics starting September 11, 2025 [6] - Xinhua Pharmaceutical's Vice President Zheng Zhonghui resigned for personal reasons, holding 397,600 shares in the company [7] 分组3 - Unified Holdings completed the change in the shareholding structure of its controlling shareholder, with the actual controller changing from the Ministry of Finance to Central Huijin Investment [8] - ST New Power's stock may face delisting risk warnings due to a negative audit opinion on its internal controls for the 2024 financial report [9] - Huachuang Yuxin announced that 1.87% of its shares held by Shanghai Shiran Industrial Co., Ltd. will be auctioned [10] 分组4 - Zhengbang Technology's subsidiary Chaoyang Zhengbang has been accepted for reorganization by the court, with total assets of RMB 332 million and liabilities of RMB 460 million as of December 31, 2024 [11] - China Shipbuilding Defense's General Manager Chen Liping resigned due to work changes [12] 分组5 - Poly Developments reported a signing amount of RMB 18.015 billion in August 2025, a year-on-year decrease of 18.54% [14] - Muyuan Foods reported sales revenue of RMB 11.85 billion from selling 7.001 million pigs in August 2025, with a year-on-year decrease of 12.30% [15] - Dongrui Co., Ltd. reported a sales revenue of RMB 160 million from selling 94,800 pigs in August 2025, a month-on-month decrease of 5.48% [16] 分组6 - Ankai Bus reported a cumulative production increase of 68.06% year-on-year, with a total production of 5,625 vehicles in 2025 [17] - Kangchen Pharmaceutical's controlling shareholder Liu Jianhua plans to reduce his stake by up to 3% [19] - Kewell plans to reduce its shares by up to 2.34% [20] 分组7 - North Special Technology plans to raise no more than RMB 300 million through a private placement for a production base project in Thailand [29] - Guangqi Technology signed contracts worth RMB 1.278 billion for the mass production of metamaterials [31][32]

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Core Points - 康辰药业's controlling shareholder, Liu Jianhua, plans to reduce his stake in the company by up to 4.7807 million shares, which represents no more than 3% of the total shares [1] Summary by Category Shareholder Actions - Liu Jianhua intends to sell shares through centralized bidding and block trading methods within three months after a 15 trading day period from the announcement date, excluding any legally mandated holding periods [1]